Published in J Bone Miner Res on March 29, 2004
FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051) | NCT00398931
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int (2007) 1.79
Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res (2014) 1.78
Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med (2014) 1.75
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (2015) 1.57
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos (2017) 1.40
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res (2010) 1.19
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
Treatment of osteoporosis in men. Bone (2012) 1.06
Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res (2009) 1.04
Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int (2008) 1.02
Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab (2007) 1.02
Femoral stress fractures associated with long-term bisphosphonate treatment. Clin Orthop Relat Res (2012) 1.01
Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab (2009) 0.99
A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int (2011) 0.98
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int (2010) 0.97
Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab (2011) 0.97
Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats. Bone (2014) 0.96
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int (2015) 0.95
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res (2008) 0.92
Adherence to alendronate in male veterans. Osteoporos Int (2007) 0.92
Potential impact of osteoporosis treatment on hip fracture trends. J Bone Miner Res (2005) 0.91
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab (2009) 0.91
The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord (2007) 0.90
Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases. Acta Orthop (2010) 0.88
Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging (2010) 0.88
Bisphosphonate drug holidays: Can we recommend currently? J Midlife Health (2014) 0.84
Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review. BMC Musculoskelet Disord (2013) 0.83
Association between fat mass, lean mass, and bone loss: the Dubbo Osteoporosis Epidemiology Study. Osteoporos Int (2015) 0.83
The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol (2016) 0.81
Osteoporosis: "A risk factor for periodontitis". J Indian Soc Periodontol (2009) 0.80
Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference. J Bone Miner Metab (2013) 0.79
Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women. Osteoporos Int (2011) 0.79
Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging (2013) 0.77
Alendronate sodium in the management of osteoporosis. Ther Clin Risk Manag (2006) 0.77
A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. J Clin Endocrinol Metab (2014) 0.76
Subtrochanteric femoral insufficiency fractures related to the use of long-term bisphosphonates: a pictorial review. Emerg Radiol (2010) 0.75
Atypical femoral shaft fractures secondary to long-term bisphosphonate therapy. J Orthop (2017) 0.75
Central dislocation of the hip secondary to insufficiency fracture. Orthop Rev (Pavia) (2010) 0.75
A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis. J Pharmacokinet Pharmacodyn (2017) 0.75
Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study. Br J Clin Pharmacol (2017) 0.75
Actions of osteoporosis treatments on bone histomorphometric remodeling: a two-fold principal component analysis. Osteoporos Int (2013) 0.75
Treatment of osteoporosis after alendronate or risedronate. Osteoporos Int (2015) 0.75
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum (2008) 19.80
2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc (2011) 13.10
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86
Prognostic value of usual gait speed in well-functioning older people--results from the Health, Aging and Body Composition Study. J Am Geriatr Soc (2005) 6.54
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med (2004) 5.69
Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol (2007) 5.23
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry (2008) 4.65
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Clinical use of bone densitometry: scientific review. JAMA (2002) 3.73
Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med (2006) 3.71
Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med (2005) 3.56
Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med (2005) 3.39
Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res (2004) 3.37
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
Objective light-intensity physical activity associations with rated health in older adults. Am J Epidemiol (2010) 3.22
Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev (2005) 3.20
Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med (2008) 3.20
Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci (2007) 3.16
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res (2002) 3.15
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (2002) 3.10
Postmenopausal Osteoporosis. N Engl J Med (2016) 3.04
Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc (2002) 3.03
Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc (2005) 3.02
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther (2008) 2.87
A drug burden index to define the functional burden of medications in older people. Arch Intern Med (2007) 2.84
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev (2012) 2.71
A new approach yields high rates of radiographic progression in knee osteoarthritis. J Rheumatol (2008) 2.63
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA (2007) 2.62
The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol (2008) 2.60
Cardiorespiratory fitness levels among US adults 20-49 years of age: findings from the 1999-2004 National Health and Nutrition Examination Survey. Am J Epidemiol (2010) 2.60
Estimating activity and sedentary behavior from an accelerometer on the hip or wrist. Med Sci Sports Exerc (2013) 2.48
Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med (2014) 2.48
Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension (2008) 2.44
Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol (2010) 2.43
Relationship of changes in physical activity and mortality among older women. JAMA (2003) 2.42
Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care (2007) 2.42
Dance and reducing television viewing to prevent weight gain in African-American girls: the Stanford GEMS pilot study. Ethn Dis (2003) 2.41
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Validation of a new brief physical activity survey among men and women aged 60-69 years. Am J Epidemiol (2006) 2.37
Hip fracture in women without osteoporosis. J Clin Endocrinol Metab (2005) 2.35
Evidence-based public health: an evolving concept. Am J Prev Med (2004) 2.35
Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail (2008) 2.33
Progression of radiographic hip osteoarthritis over eight years in a community sample of elderly white women. Arthritis Rheum (2004) 2.32
Central nervous system active medications and risk for fractures in older women. Arch Intern Med (2003) 2.30
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29
Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med (2011) 2.27
Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med (2012) 2.24
Effect of Mindfulness-Based Stress Reduction in rheumatoid arthritis patients. Arthritis Rheum (2007) 2.23
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res (2004) 2.23
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc (2010) 2.19
Mild intraoperative hypothermia during surgery for intracranial aneurysm. N Engl J Med (2005) 2.17
The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum (2007) 2.16
Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin (2004) 2.11
The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol (2013) 2.10
Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 2.10
Variation of patient characteristics, management, and outcome with timing of surgery for aneurysmal subarachnoid hemorrhage. J Neurosurg (2011) 2.09
Association of major and minor ECG abnormalities with coronary heart disease events. JAMA (2012) 2.07
Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke (2011) 2.07
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res (2011) 2.07
Epidemiologic association between prostatitis and prostate cancer. Urology (2002) 2.05
Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA (2011) 2.04
Safety and efficacy of a ginkgo biloba-containing dietary supplement on cognitive function, quality of life, and platelet function in healthy, cognitively intact older adults. J Am Diet Assoc (2007) 2.04
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab (2006) 2.02
Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum (2004) 2.01
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ (2009) 2.00
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
Fatness, physical activity, and television viewing in children during the adiposity rebound period: the Iowa Bone Development Study. Prev Med (2002) 1.97
Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc (2002) 1.97
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc (2002) 1.97
Age-related differences in unruptured intracranial aneurysms: 1-year outcomes. J Neurosurg (2014) 1.96
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res (2010) 1.95
Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum (2003) 1.93
Circulating 25-hydroxyvitamin D levels and frailty status in older women. J Clin Endocrinol Metab (2010) 1.93
Racial variation in the relationship of anemia with mortality and mobility disability among older adults. Blood (2007) 1.92